Neurogene Inc

The stock maintains a bullish medium- and long-term structure, anchored by rising major moving averages and a sequence of higher lows. A recent pullback into the 9/21 EMA support zone was absorbed, signaling acceptance and a favorable entry bias. RSI holds in neutral territory, avoiding overbought extremes. Execution is recommended now, buying into minor pullbacks toward the EMA support area.

• ↑Phase 1/2 NGN-401 trial saw 100% participants improving, averaging 4.7 milestones
• ↑Analysts’ average $83.67 target implies ~135% potential upside
• ↓Q2 net loss of $34.5M (-$1.53/share) underscores cash burn